Posted by Michael Wonder on 12 Jul 2022
Provepharm announces that it has received FDA approval for Bludigo (indigotindisulfonate sodium, USP) injection
12 July 2022 - Bludigo is the first and only indigotindisulfonate sodium injection, USP, drug product approved by the FDA.
Provepharm today announced that it has received FDA new drug approval for the marketing of its injectable Bludigo (indigotindisulfonate sodium) Injection.
Bludogo is a diagnostic dye indicated for use as a visualisation aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynaecological open, robotic, or endoscopic surgical procedures.
